U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264205) titled 'RT-310 Safety and Feasibility BPH Study' on Nov. 24.
Brief Summary: RT-310, is intended to deliver drug locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.
Study Start Date: March 13
Study Type: INTERVENTIONAL
Condition:
BPH (Benign Prostatic Hyperplasia)
Intervention:
COMBINATION_PRODUCT: RT-310
RT-310
Recruitment Status: RECRUITING
Sponsor: Resurge Therapeutics Inc.
Published by HT Digital Content Services with permission from He...